Email Alert RSS
Volume 13 Issue 5
Sep.  2022
Turn off MathJax
Article Contents
Abstract
References
Related Articles
MA Dongjiang, DENG Chengwu, WEI Cheng, LYU Bingzhe, WANG Chen. Characteristics of Transcription Factor POU3F2 and Its Research Progress in Tumorigenesis and Development[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(5): 858-863. DOI: 10.12290/xhyxzz.2022-0008
Citation: MA Dongjiang, DENG Chengwu, WEI Cheng, LYU Bingzhe, WANG Chen. Characteristics of Transcription Factor POU3F2 and Its Research Progress in Tumorigenesis and Development[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(5): 858-863. DOI: 10.12290/xhyxzz.2022-0008
shu

Characteristics of Transcription Factor POU3F2 and Its Research Progress in Tumorigenesis and Development

  • Department of General Surgery, Lanzhou University Second Hospital, Lanzhou 730000, China

Funds: 

Science and Technology Major Special Collaboration Project of Gansu Province 19ZD2WA001

More Information
  • Corresponding author:

    WANG Chen, E-mail: chenwang@lzu.edu.cn

  • Received Date: January 04, 2022
  • Accepted Date: February 20, 2022
  • Available Online: August 14, 2022
  • Issue Publish Date: September 29, 2022
    Graphical Abstract
    • Abstract
  • In recent years, with more and more basic research on the POU family, it has been found that POU domain proteins are related to cell development, replication, growth, and cell cycle blocking and differentiation. POU3F2 not only participates in embryonic development and differentiation of central neuroendocrine system, but also has wide expression in malignant tumors, and regulates the proliferation, invasion and metastasis of tumor cells in different ways to affect tumor development. Based on the structure of POU3F2, the review expounds the function and research status of POU3F2 in common malignant tumors, with the hope of further studying its mechanism and preventing diseases.
    • FullText(HTML)
    • References (37)
  • [1]
    Herr W, Sturm RA, Clerc RG, et al. The POU domain: a large conserved region in the mammalian pit-1, oct-1, oct-2, and Caenorhabditis elegans unc-86 gene products[J]. Genes Dev, 1988, 2: 1513-1516.
    [2]
    Wegner M, Drolet DW, Rosenfeld MG. POU-domain proteins: structure and function of developmental regulators[J]. Curr Opin Cell Biol, 1993, 5: 488-498.
    [3]
    Tantin D. Oct transcription factors in development and stem cells: insights and mechanisms[J]. Development, 2013, 140: 2857-2866. DOI: 10.1242/dev.095927
    [4]
    Smit DJ, Smith AG, Parsons PG, et al. Domains of Brn-2 that mediate homodimerization and interaction with general and melanocytic transcription factors[J]. Eur J Biochem, 2000, 267: 6413-6422.
    [5]
    Schonemann MD, Ryan AK, McEvilly RJ, et al. Development and survival of the endocrine hypothalamus and posterior pituitary gland requires the neuronal POU domain factor Brn-2[J]. Genes Dev, 1995, 9: 3122-3135. DOI: 10.1101/gad.9.24.3122
    [6]
    Atanasoski S, Toldo SS, Malipiero U, et al. Isolation of the human genomic brain-2/N-Oct 3 gene (POUF3) and assignment to chromosome 6q16[J]. Genomics, 1995, 26: 272-280. DOI: 10.1016/0888-7543(95)80211-4
    [7]
    Nakai S, Kawano H, Yudate T, et al. The POU domain transcription factor Brn-2 is required for the determination of specific neuronal lineages in the hypothalamus of the mouse[J]. Genes Dev, 1995, 9: 3109-3121. DOI: 10.1101/gad.9.24.3109
    [8]
    Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary[J]. Acta Neuropathol, 2016, 131: 803-820. DOI: 10.1007/s00401-016-1545-1
    [9]
    Fujikawa A, Sugawara H, Tanaka T, et al. Targeting PTPRZ inhibits stem cell-like properties and tumorigenicity in glioblastoma cells[J]. Sci Rep, 2017, 7: 5609. DOI: 10.1038/s41598-017-05931-8
    [10]
    Suvà ML, Rheinbay E, Gillespie SM, et al. Reconstruct-ing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells[J]. Cell, 2014, 157: 580-594. DOI: 10.1016/j.cell.2014.02.030
    [11]
    Perotti V, Baldassari P, Molla A, et al. NFATc2 is an intrinsic regulator of melanoma dedifferentiation[J]. Oncogene, 2016, 35: 2862-2872. DOI: 10.1038/onc.2015.355
    [12]
    Yang F, Cui P, Lu Y, et al. Requirement of the transcription factor YB-1 for maintaining the stemness of cancer stem cells and reverting differentiated cancer cells into cancer stem cells[J]. Stem Cell Res Ther, 2019, 10: 233. DOI: 10.1186/s13287-019-1360-4
    [13]
    Perdana NR, Mochtar CA, Umbas R, et al. The Risk Factors of Prostate Cancer and Its Prevention: A Literature Review[J]. Acta Med Indones, 2016, 48: 228-238.
    [14]
    Bishop JL, Thaper D, Vahid S, et al. The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer[J]. Cancer Discov, 2017, 7: 54-71. DOI: 10.1158/2159-8290.CD-15-1263
    [15]
    Beltran H, Tomlins S, Aparicio A, et al. Aggressive variants of castration-resistant prostate cancer[J]. Clin Cancer Res, 2014, 20: 2846-2850. DOI: 10.1158/1078-0432.CCR-13-3309
    [16]
    Bhagirath D, Yang TL, Tabatabai ZL, et al. BRN4 Is a Novel Driver of Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer and Is Selectively Released in Extracellular Vesicles with BRN2[J]. Clin Cancer Res, 2019, 25: 6532-6545. DOI: 10.1158/1078-0432.CCR-19-0498
    [17]
    Fenner A. Prostate cancer: BRN2 is a neuroendocrine driver[J]. Nat Rev Urol, 2017, 14: 10.
    [18]
    Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses[J]. Proc Natl Acad Sci U S A, 2001, 98: 13790-13795. DOI: 10.1073/pnas.191502998
    [19]
    Ishii J, Sato H, Yazawa T, et al. Class Ⅲ/Ⅳ POU transcription factors expressed in small cell lung cancer cells are involved in proneural/neuroendocrine differentiation[J]. Pathol Int, 2014, 64: 415-422. DOI: 10.1111/pin.12198
    [20]
    Ishii J, Sato H, Sakaeda M, et al. POU domain transcription factor BRN2 is crucial for expression of ASCL1, ND1 and neuroendocrine marker molecules and cell growth in small cell lung cancer[J]. Pathol Int, 2013, 63: 158-168. DOI: 10.1111/pin.12042
    [21]
    Sakaeda M, Sato H, Ishii J, et al. Neural lineage-specific homeoprotein BRN2 is directly involved in TTF1 expression in small-cell lung cancer[J]. Lab Invest, 2013, 93: 408-421. DOI: 10.1038/labinvest.2013.2
    [22]
    He Y, Peng X, Zheng L, et al. Asiaticoside inhibits epithelial-mesenchymal transition and stem cell-like properties of pancreatic cancer PANC-1 cells by blocking the activation of p65 and p38MAPK[J]. J Gastrointest Oncol, 2021, 12: 196-206. DOI: 10.21037/jgo-20-533
    [23]
    Luan Z, Morimoto Y, Fushimi A, et al. MUC1-C Dictates Neuroendocrine Lineage Specification in Pancreatic Ductal Adenocarcinomas[J]. Carcinogenesis, 2022, 43: 67-76. DOI: 10.1093/carcin/bgab097
    [24]
    Zeng H, Jorapur A, Shain AH, et al. Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation[J]. Cancer Cell, 2018, 34: 56-68. e9. DOI: 10.1016/j.ccell.2018.05.014
    [25]
    Fane ME, Chhabra Y, Hollingsworth D, et al. NFIB Mediates BRN2 Driven Melanoma Cell Migration and Invasion Through Regulation of EZH2 and MITF[J]. EBioMedicine, 2017, 16: 63-75. DOI: 10.1016/j.ebiom.2017.01.013
    [26]
    Chen HY, Lee YH, Chen HY, et al. Capsaicin Inhibited Aggressive Phenotypes through Downregulation of Tumor-Associated NADH Oxidase (tNOX) by POU Domain Transcription Factor POU3F2[J]. Molecules, 2016, 21: 733.
    [27]
    Li H, Gao C, Zhuang J, et al. An mRNA characterization model predicting survival in patients with invasive breast cancer based on The Cancer Genome Atlas database[J]. Cancer Biomark, 2021, 30: 417-428. DOI: 10.3233/CBM-201684
    [28]
    Miskin RP, Warren J, Ndoye A, et al. Integrin α3β1 Promotes Invasive and Metastatic Properties of Breast Cancer Cells through Induction of the Brn-2 Transcription Factor[J]. Cancers (Basel), 2021, 13: 480. DOI: 10.3390/cancers13030480
    [29]
    Hamm M, Sohier P, Petit V, et al. BRN2 is a non-canonical melanoma tumor-suppressor[J]. Nat Commun, 2021, 12: 3707. DOI: 10.1038/s41467-021-23973-5
    [30]
    Herbert K, Binet R, Lambert JP, et al. BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associ-ated with a high somatic mutation burden in melanoma[J]. Genes Dev, 2019, 33: 310-332. DOI: 10.1101/gad.314633.118
    [31]
    Cui T, Bell EH, McElroy J, et al. A Novel miR-146a-POU3F2/SMARCA5 Pathway Regulates Stemness and Therapeutic Response in Glioblastoma[J]. Mol Cancer Res, 2021, 19: 48-60. DOI: 10.1158/1541-7786.MCR-20-0353
    [32]
    Zhao G, Wei Z, Guo Y. MicroRNA-107 is a novel tumor suppressor targeting POU3F2 in melanoma[J]. Biol Res, 2020, 53: 11.
    [33]
    Goodall J, Wellbrock C, Dexter TJ, et al. The Brn-2 transcription factor links activated BRAF to melanoma proliferation[J]. Mol Cell Biol, 2004, 24: 2923-2931. DOI: 10.1128/MCB.24.7.2923-2931.2004
    [34]
    Bonvin E, Falletta P, Shaw H, et al. A phosphatidylino-sitol 3-kinase-Pax3 axis regulates Brn-2 expression in melanoma[J]. Mol Cell Biol, 2012, 32: 4674-4683. DOI: 10.1128/MCB.01067-12
    [35]
    Chen HY, Islam A, Yuan TM, et al. Regulation of tNOX expression through the ROS-p53-POU3F2 axis contributes to cellular responses against oxaliplatin in human colon cancer cells[J]. J Exp Clin Cancer Res, 2018, 37: 161. DOI: 10.1186/s13046-018-0837-9
    [36]
    Ding S, Jin Y, Hao Q, et al. LncRNA BCYRN1/miR-490-3p/POU3F2, served as a ceRNA network, is connec-ted with worse survival rate of hepatocellular carcinoma patients and promotes tumor cell growth and metastasis[J]. Cancer Cell Int, 2020, 20: 6. DOI: 10.1186/s12935-019-1081-x
    [37]
    Fan W, Chen L, Wu X, et al. Circ_ 0031242 Silencing Mitigates the Progression and Drug Resistance in DDP-Resistant Hepatoma Cells by the miR-924/POU3F2 Axis[J]. Cancer Manag Res, 2021, 13: 743-755. DOI: 10.2147/CMAR.S272851
    • Related Articles

  • Related Articles

    [1]YAN Xinchun, HUO Li. Evaluation of Von Hippel-Lindau Syndrome Through Novel Small Molecular Tracer 68Ga-NY104 PET/CT Imaging[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(4): 911-915. DOI: 10.12290/xhyxzz.2024-0216
    [2]LIU Wanrong, TANG Hui, ZHOU Na, QIU Wei, LI Xiaoyuan, WANG Xiang, BAI Chunmei, ZHOU Jianfeng, ZHAO Lin. Incidence of COVID-19 in Patients with Tumor During the Omicron Pandemic[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(6): 1238-1245. DOI: 10.12290/xhyxzz.2023-0281
    [3]LIU Yuan, ZHAO Lin. Update and Interpretation of 2022 National Comprehensive Cancer Network Clinical Practice Guidelines for Gastric Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 999-1004. DOI: 10.12290/xhyxzz.2022-0271
    [4]ZHANG Shan, LIU Zhaorui, LIU Jie. Relationship Between SerpinB9 and Tumors and Research Progress of SerpinB9 in Skin Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(5): 852-857. DOI: 10.12290/xhyxzz.2021-0805
    [5]WANG Shijun, LI Yingjie, WEN Jin. Advances in Urinary Tumor Markers of Prostate Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(4): 652-657. DOI: 10.12290/xhyxzz.2021-0774
    [6]XIAO Nan, LI Zhanfeng, YAO Jianxin, PAN Zhiyao, YAO Zhifeng. Long Non-coding RNA and Cancer Stem Cells[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(3): 373-379. DOI: 10.12290/xhyxzz.20190231
    [7]PENG Li, ZHAO Jia-lin, ZHAO Da-chun, ZHANG Zhen, MAO Feng, SUN Qiang. Clinicopathological Features and Lymph Node Metastasis-related Factors of Primary Neuroendocrine Breast Cancer and Invasive Breast Cancer of Nonspecial Type: A Case-control Study[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(1): 122-128. DOI: 10.12290/xhyxzz.20190108
    [8]Cheng HUANG, Ye-ye CHEN, Shan-qing LI, Xiao-yun ZHOU, Hong-sheng LIU, Li LI, Ying-zhi QIN, Jia HE, Dong-jie MA. Ectopic Adrenocorticotropic Hormone Syndrome Caused by Thoracic Neuroendocrine Tumors: Surgical Treatment and Prognosis Factors[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(2-3): 147-153. DOI: 10.3969/j.issn.1674-9081.2017.03.012
    [9]Zhi-peng MAI, Wei-gang YAN, Zhi-gang JI, Han-zhong LI, Fu-quan ZHANG, Ke HU, Yu XIAO. Clinical Characteristics of Gleason Score 10 Prostate Cancer on Core Biopsy without Distant Metastases at Initial Diagnosis[J]. Medical Journal of Peking Union Medical College Hospital, 2016, 7(4): 275-279. DOI: 10.3969/j.issn.1674-9081.2016.04.007
    [10]Ye-ye CHEN, Hong-sheng LIU, Shan-qing LI, Cheng HUANG, Li LI, Ying-zhi QIN. Neuroendocrine Tumors of the Thymus: Outcomes after Surgical Resection and Prognostic Factors[J]. Medical Journal of Peking Union Medical College Hospital, 2016, 7(3): 190-194. DOI: 10.3969/j.issn.1674-9081.2016.03.006

  • Cited by

    Periodical cited type(1)

    1. 孙婧，杨自宇，王鹏丽，王彤彤，刘慧荣，张苏丽. 孕期血管紧张素Ⅱ1型受体自身抗体暴露抑制胎鼠肝脏发育. 中华围产医学杂志. 2024(04): 301-311 .

    Other cited types(0)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (467) PDF downloads (23) Cited by(1)
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close